ARTISTRY-7
14 Sep 2023
Trial Summary
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator’s choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Acronym:
ARTISTRY-7
ACTRN/NCT /ethics:
NCT05092360
Scientific title:
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Sponsor / Cooperative group:
Alkermes, Inc.
Trial & Patient Characteristics
| Cancer Type | Female reproductive system |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Female |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2022-01-10 |
| Anticipated End Date | 2026-12-01 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead/Kate Penta |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Meena Okera |
| Recruitment Status | Recruiting |